Cannabis Poland Valuation
Is CBD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Book gegen Gleichaltrige
Price-To-Book gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of CBD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von CBD für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von CBD für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CBD?
Other financial metrics that can be useful for relative valuation.
| What is CBD's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | zł29.03m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 426.9x |
| Enterprise Value/EBITDA | -25.9x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does CBD's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.6x | ||
LCN Labocanna | 1.4x | n/a | zł9.6m |
BGD Biogened | 1.8x | n/a | zł63.4m |
MOC Molecure | 1.7x | -6.3% | zł284.5m |
CLN Celon Pharma | 1.7x | 59.1% | zł777.1m |
CBD Cannabis Poland | 21.3x | n/a | zł29.0m |
Price-To-Book gegen Gleichaltrige: CBD ist auf der Grundlage des Price-To-Book Verhältnisses (15.8x) im Vergleich zum Durchschnitt der Vergleichsgruppe (1.8x) teuer.
Price to Earnings Ratio vs Industry
How does CBD's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Book gegen Industrie: CBD ist teuer, wenn man sein Price-To-Book Verhältnis (15.8x) mit dem European Pharmaceuticals Branchendurchschnitt (2.1x) vergleicht.
Price to Book Ratio vs Fair Ratio
What is CBD's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 21.3x |
| Fair PB Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Book Fair Ratio von CBD für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.